Active Needle Technology Ltd. is excited to announce the latest pre-clinical news about its HyPerfuse Needle™.
Our revolutionary, ultrasound-mediated drug delivery device has now gained laboratory verified proof of its ability to deliver clinically significant improvements in intratumoural drug perfusion in a tumour bearing mouse model.
Working with oncologists in association with a leading UK university, a recent pre-clinical study has confirmed that intratumoural drug delivery with the HyPerfuse Needle™ offers vastly superior rates of cancer killing efficacy when compared to a standard needle.
This represents a step change in drug delivery technology. Finally; a novel device to compliment and optimise the performance of therapeutic pharmaceuticals and biologics; a solution to the poor drug efficacy attributed to standard intratumoural delivery techniques and limited dispersion profiles.
HyPerfuse Needle™ also solves the problem of accurately targeting the exact site for the tumour injection. The active HyPerfuse Needle™ is highly visible under Doppler ultrasound, allowing the clinician to accurately target the desired tumour entry point with unparalleled visualisation. This ensures that any therapeutic agents, such as small molecules, viruses, peptides, nanoparticles, vesicles, and biologics are precisely placed inside the tumour with an unprecedented distribution profile.
We are excited to collaborate with partners that can utilise the HyPerfuse Needle™ and enhance intratumoural cancer therapies as significantly more tumour tissue receives the therapeutic agent.
Contact us at <mailto:info@activeneedle.com> info@activeneedle.com to
learn more.
